Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

33.80
+0.02710.08%
Post-market: 33.77-0.0271-0.08%16:10 EDT
Volume:222
Turnover:8K
Market Cap:13.52M
PE:- -
High:33.80
Open:33.77
Low:33.80
Close:33.77
52wk High:34.98
52wk Low:27.25
Shares:400.00K
Float Shares:400.00K
Volume Ratio:0.14
T/O Rate:0.06%
Dividend:0.08
Dividend Rate:0.24%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

TD Cowen Adjusts Merck Price Target to $155 From $137, Maintains Hold Rating

MT Newswires Live
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Celldex (CLDX) and Inventiva (IVA)

TIPRANKS
·
Sep 23

Kimberly-Clark Offers Remedies in Bid for EU Approval of Kenvue Deal

Reuters
·
Sep 23

Jiangsu Hengrui Pharmaceuticals Secures Clinical Trial Approvals for Ten Drug Candidates

Stock News
·
Sep 23

Guangdong Taienkang Pharmaceutical's Subsidiary Reports Positive Phase IIa Interim Findings for CKBA Cream in Rosacea Treatment

Stock News
·
Sep 23

Merck & Co Inc : TD Cowen Raises Target Price to $155 from $137

THOMSON REUTERS
·
Sep 23

Medtronic PLC Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 23

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 23

Wall Street Analysts Are Neutral on Top Healthcare Picks

TIPRANKS
·
Sep 23

New precision medicine venture gives Syngenis added firepower

The West Australian
·
Sep 23

Dow Falls 134 Points on Losses for Shares of Cisco, JPMorgan Chase

Dow Jones
·
Sep 22

Lucid Diagnostics advances Medicare reimbursement and coding infrastructure

TIPRANKS
·
Sep 22

Changchun High-Tech Receives Acceptance Notice for Clinical Trial Application of RSV Antibody Combination Injection

Stock News
·
Sep 22

DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026

Reuters
·
Sep 22

J&J DePuy Synthes to Showcase Next-Generation Trauma Devices at Orthopaedic Trauma Association Annual Meeting

Reuters
·
Sep 22

Changchun Bcht Biotechnology Wins Acceptance for RSV Antibody Trial Application

Stock News
·
Sep 22

Merck Gets FDA Label Update for WINREVAIR Based on HYPERION Trial

MT Newswires Live
·
Sep 22

Merck says FDA approves update for U.S. product label for Winrevair

TIPRANKS
·
Sep 22

U.S. FDA Approves Update to the Label for Winrevair to Include Data from the Phase 3 Hyperion Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension

Reuters
·
Sep 22

Merck Says Phase 3 Hyperion Trial Shows Winrevair Cuts PAH Clinical Worsening Risk 76%

Reuters
·
Sep 22